Skip to content

TriangleGet started

← Full study record

NCT03141177 · OUTCOME

Number of Participants With Laboratory Abnormalities

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · Source last updated 2026-08-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From first dose to 30 days following last dose (Up to 30 Months)

What was measured

Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.

Analysis population: All Treated Participants

Groups in this outcome

Treatment A

Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment B

Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment C

Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment A	320
Treatment B	50
Treatment C	320

Reported measurements

Hemoglobin: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	235	Not reported	Not reported	Not reported	Not reported
Treatment B	35	Not reported	Not reported	Not reported	Not reported
Treatment C	256	Not reported	Not reported	Not reported	Not reported

Hemoglobin: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	9	Not reported	Not reported	Not reported	Not reported
Treatment B	5	Not reported	Not reported	Not reported	Not reported
Treatment C	15	Not reported	Not reported	Not reported	Not reported

Platelet Count: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	137	Not reported	Not reported	Not reported	Not reported
Treatment B	27	Not reported	Not reported	Not reported	Not reported
Treatment C	216	Not reported	Not reported	Not reported	Not reported

Platelet Count: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	1	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	30	Not reported	Not reported	Not reported	Not reported

Leukocytes: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	121	Not reported	Not reported	Not reported	Not reported
Treatment B	26	Not reported	Not reported	Not reported	Not reported
Treatment C	207	Not reported	Not reported	Not reported	Not reported

Leukocytes: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	1	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	16	Not reported	Not reported	Not reported	Not reported

Lymphocytes: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	231
Treatment B	36
Treatment C	231

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	107	Not reported	Not reported	Not reported	Not reported
Treatment B	22	Not reported	Not reported	Not reported	Not reported
Treatment C	118	Not reported	Not reported	Not reported	Not reported

Lymphocytes: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	231
Treatment B	36
Treatment C	231

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	16	Not reported	Not reported	Not reported	Not reported
Treatment B	4	Not reported	Not reported	Not reported	Not reported
Treatment C	24	Not reported	Not reported	Not reported	Not reported

Neutrophil: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	115	Not reported	Not reported	Not reported	Not reported
Treatment B	22	Not reported	Not reported	Not reported	Not reported
Treatment C	209	Not reported	Not reported	Not reported	Not reported

Neutrophil: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	10	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	36	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	194	Not reported	Not reported	Not reported	Not reported
Treatment B	35	Not reported	Not reported	Not reported	Not reported
Treatment C	167	Not reported	Not reported	Not reported	Not reported

Alkaline Phosphatase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	12	Not reported	Not reported	Not reported	Not reported
Treatment B	6	Not reported	Not reported	Not reported	Not reported
Treatment C	6	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase (AST): Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	260	Not reported	Not reported	Not reported	Not reported
Treatment B	43	Not reported	Not reported	Not reported	Not reported
Treatment C	235	Not reported	Not reported	Not reported	Not reported

Aspartate Aminotransferase (AST): Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	25	Not reported	Not reported	Not reported	Not reported
Treatment B	19	Not reported	Not reported	Not reported	Not reported
Treatment C	8	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase (ALT): Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	268	Not reported	Not reported	Not reported	Not reported
Treatment B	46	Not reported	Not reported	Not reported	Not reported
Treatment C	133	Not reported	Not reported	Not reported	Not reported

Alanine Aminotransferase (ALT): Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	31	Not reported	Not reported	Not reported	Not reported
Treatment B	24	Not reported	Not reported	Not reported	Not reported
Treatment C	11	Not reported	Not reported	Not reported	Not reported

Bilirubin: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	57	Not reported	Not reported	Not reported	Not reported
Treatment B	17	Not reported	Not reported	Not reported	Not reported
Treatment C	72	Not reported	Not reported	Not reported	Not reported

Bilirubin: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	3	Not reported	Not reported	Not reported	Not reported
Treatment B	3	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Creatinine: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	221	Not reported	Not reported	Not reported	Not reported
Treatment B	34	Not reported	Not reported	Not reported	Not reported
Treatment C	211	Not reported	Not reported	Not reported	Not reported

Creatinine: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	4	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	2	Not reported	Not reported	Not reported	Not reported

Amylase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	295
Treatment B	46
Treatment C	283

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	48	Not reported	Not reported	Not reported	Not reported
Treatment B	28	Not reported	Not reported	Not reported	Not reported
Treatment C	41	Not reported	Not reported	Not reported	Not reported

Amylase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	295
Treatment B	46
Treatment C	283

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	30	Not reported	Not reported	Not reported	Not reported
Treatment B	10	Not reported	Not reported	Not reported	Not reported
Treatment C	17	Not reported	Not reported	Not reported	Not reported

Lipase: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	48
Treatment C	306

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	36	Not reported	Not reported	Not reported	Not reported
Treatment B	27	Not reported	Not reported	Not reported	Not reported
Treatment C	42	Not reported	Not reported	Not reported	Not reported

Lipase: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	48
Treatment C	306

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	46	Not reported	Not reported	Not reported	Not reported
Treatment B	20	Not reported	Not reported	Not reported	Not reported
Treatment C	41	Not reported	Not reported	Not reported	Not reported

Hypernatremia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	33	Not reported	Not reported	Not reported	Not reported
Treatment B	7	Not reported	Not reported	Not reported	Not reported
Treatment C	24	Not reported	Not reported	Not reported	Not reported

Hypernatremia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hyponatremia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	160	Not reported	Not reported	Not reported	Not reported
Treatment B	31	Not reported	Not reported	Not reported	Not reported
Treatment C	140	Not reported	Not reported	Not reported	Not reported

Hyponatremia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	36	Not reported	Not reported	Not reported	Not reported
Treatment B	9	Not reported	Not reported	Not reported	Not reported
Treatment C	41	Not reported	Not reported	Not reported	Not reported

Hyperkalemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	136	Not reported	Not reported	Not reported	Not reported
Treatment B	27	Not reported	Not reported	Not reported	Not reported
Treatment C	100	Not reported	Not reported	Not reported	Not reported

Hyperkalemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	16	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	3	Not reported	Not reported	Not reported	Not reported

Hypokalemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	64	Not reported	Not reported	Not reported	Not reported
Treatment B	8	Not reported	Not reported	Not reported	Not reported
Treatment C	37	Not reported	Not reported	Not reported	Not reported

Hypokalemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	317
Treatment B	49
Treatment C	311

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	11	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	6	Not reported	Not reported	Not reported	Not reported

Hypercalcemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	315
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	40	Not reported	Not reported	Not reported	Not reported
Treatment B	9	Not reported	Not reported	Not reported	Not reported
Treatment C	58	Not reported	Not reported	Not reported	Not reported

Hypercalcemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	315
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	1	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	4	Not reported	Not reported	Not reported	Not reported

Hypocalcemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	315
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	174	Not reported	Not reported	Not reported	Not reported
Treatment B	25	Not reported	Not reported	Not reported	Not reported
Treatment C	77	Not reported	Not reported	Not reported	Not reported

Hypocalcemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	315
Treatment B	48
Treatment C	310

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	6	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	2	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	42	Not reported	Not reported	Not reported	Not reported
Treatment B	9	Not reported	Not reported	Not reported	Not reported
Treatment C	29	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	12	Not reported	Not reported	Not reported	Not reported
Treatment B	4	Not reported	Not reported	Not reported	Not reported
Treatment C	7	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	155	Not reported	Not reported	Not reported	Not reported
Treatment B	18	Not reported	Not reported	Not reported	Not reported
Treatment C	90	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	4	Not reported	Not reported	Not reported	Not reported
Treatment B	1	Not reported	Not reported	Not reported	Not reported
Treatment C	1	Not reported	Not reported	Not reported	Not reported

Hyperphosphatemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hyperphosphatemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	0	Not reported	Not reported	Not reported	Not reported
Treatment B	0	Not reported	Not reported	Not reported	Not reported
Treatment C	0	Not reported	Not reported	Not reported	Not reported

Hypophosphatemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	226	Not reported	Not reported	Not reported	Not reported
Treatment B	34	Not reported	Not reported	Not reported	Not reported
Treatment C	154	Not reported	Not reported	Not reported	Not reported

Hypophosphatemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	316
Treatment B	49
Treatment C	309

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	88	Not reported	Not reported	Not reported	Not reported
Treatment B	12	Not reported	Not reported	Not reported	Not reported
Treatment C	31	Not reported	Not reported	Not reported	Not reported

Hyperglycemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	203
Treatment B	37
Treatment C	196

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	135	Not reported	Not reported	Not reported	Not reported
Treatment B	29	Not reported	Not reported	Not reported	Not reported
Treatment C	139	Not reported	Not reported	Not reported	Not reported

Hyperglycemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	203
Treatment B	37
Treatment C	196

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	8	Not reported	Not reported	Not reported	Not reported
Treatment B	2	Not reported	Not reported	Not reported	Not reported
Treatment C	4	Not reported	Not reported	Not reported	Not reported

Hypoglycemia: Any grade

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	295

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	72	Not reported	Not reported	Not reported	Not reported
Treatment B	10	Not reported	Not reported	Not reported	Not reported
Treatment C	41	Not reported	Not reported	Not reported	Not reported

Hypoglycemia: Grade 3-4

Analysis denominator · Participants

Group	Source count
Treatment A	308
Treatment B	49
Treatment C	295

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment A	2	Not reported	Not reported	Not reported	Not reported
Treatment B	1	Not reported	Not reported	Not reported	Not reported
Treatment C	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
235
group Id
OG001
value
35
group Id
OG002
value
256
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Hemoglobin: Any grade
categories
measurements
group Id
OG000
value
9
group Id
OG001
value
5
group Id
OG002
value
15
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Hemoglobin: Grade 3-4
categories
measurements
group Id
OG000
value
137
group Id
OG001
value
27
group Id
OG002
value
216
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Platelet Count: Any grade
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
30
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Platelet Count: Grade 3-4
categories
measurements
group Id
OG000
value
121
group Id
OG001
value
26
group Id
OG002
value
207
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Leukocytes: Any grade
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
16
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Leukocytes: Grade 3-4
categories
measurements
group Id
OG000
value
107
group Id
OG001
value
22
group Id
OG002
value
118
denoms
counts
group Id
OG000
value
231
group Id
OG001
value
36
group Id
OG002
value
231
units
Participants
title
Lymphocytes: Any grade
categories
measurements
group Id
OG000
value
16
group Id
OG001
value
4
group Id
OG002
value
24
denoms
counts
group Id
OG000
value
231
group Id
OG001
value
36
group Id
OG002
value
231
units
Participants
title
Lymphocytes: Grade 3-4
categories
measurements
group Id
OG000
value
115
group Id
OG001
value
22
group Id
OG002
value
209
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Neutrophil: Any grade
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
2
group Id
OG002
value
36
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Neutrophil: Grade 3-4
categories
measurements
group Id
OG000
value
194
group Id
OG001
value
35
group Id
OG002
value
167
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Alkaline Phosphatase: Any grade
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
6
group Id
OG002
value
6
denoms
counts
group Id
OG000
value
317
group Id
OG001
value
49
group Id
OG002
value
311
units
Participants
title
Alkaline Phosphatase: Grade 3-4

denoms

counts
group Id
OG000
value
320
group Id
OG001
value
50
group Id
OG002
value
320
units
Participants

description

Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.

groups

description
Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
id
OG000
title
Treatment A
description
Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
id
OG001
title
Treatment B
description
Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle
id
OG002
title
Treatment C

param Type

COUNT_OF_PARTICIPANTS

population Description

All Treated Participants

reporting Status

POSTED

time Frame

From first dose to 30 days following last dose (Up to 30 Months)

title

Number of Participants With Laboratory Abnormalities

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice